India Debates Phytopharmaceutical Regulations: “New Drug” Standards vs. ASU Model

**Phytopharmaceuticals in India Face Regulatory Crossroads**

A debate has emerged regarding the optimal regulatory framework for phytopharmaceuticals in India, with arguments presented for maintaining “New Drug”-style regulations versus adopting a more liberalized approach akin to that used for Ayurveda, Siddha, and Unani (ASU) drugs. The discussion also considers the potential drawbacks of genericization in this sector. The central question revolves around how to best balance innovation, patient safety, and the integration of traditional medicine with modern scientific standards.

Currently, phytopharmaceuticals are subject to regulations similar to those governing new drugs, a framework some argue should remain in place to ensure quality and efficacy. Proponents of this stricter approach believe it is essential for fostering innovation while safeguarding public health. Conversely, others advocate for a more relaxed regulatory environment, drawing parallels with the ASU drug system, which they suggest could promote wider access and affordability. However, concerns exist that such liberalization could compromise quality control and potentially lead to the counterproductive genericization of phytopharmaceutical products, hindering further research and development in the field.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 4, 2026

Author

GOAI